Break the Chain: Leprosy in India and the 2027 Goal

The Lift Line

“A disease that is no longer counted is not a disease that is gone.”

Why This Editorial Matters for Your Exam

The Hindu’s lead editorial of 7 October 2026, “Break the chain”, examines why India, which declared leprosy eliminated as a public health problem two decades ago, is now falling behind the targets of its National Strategic Plan (NSP) and Roadmap for Leprosy 2023-2027. It follows the paper’s report on the programme’s 2025-26 annual report, which we covered in a 4 October deep dive on child leprosy cases.

The editorial is useful well beyond leprosy. It is a case study in how health indicators can mislead: a programme can hit its prevalence target while the disease keeps spreading. The same lesson applies to tuberculosis, malaria and kala-azar, and to any target that measures what is easy to count rather than what matters.

GS Paper 2: Issues relating to development and management of the social sector and services relating to health; government policies and interventions; vulnerable sections. GS Paper 1: Social issues (stigma, marginalised groups). Essay: “What gets measured gets managed.”

Background and Context

Leprosy in brief

How India got here

The two measures that matter

• Prevalence counts patients on treatment at a point in time. It falls quickly when treatment is shorter, even if new infections continue.
• Incidence counts new cases in a year. Rising child incidence and disability at diagnosis are the clearest signs that transmission continues and that diagnosis is late: a child with leprosy must have been infected recently, by someone in the community.

The NSP defines a district as having interrupted transmission when it reports no new indigenous child cases for five consecutive years.

The Analysis

1. The complacency after 2005. The editorial’s sharpest point is historical. Once prevalence fell below 1 per 10,000 and India declared that it had eliminated leprosy as a public health problem, the government “became complacent” and folded the dedicated surveillance programme into the general health system. Specialised staff and skills thinned. At the same time, shorter MDT regimens reduced the period for which patients stayed formally registered. The result was a statistical illusion: prevalence fell while transmission continued.

2. The warning signs that followed. Disability due to leprosy began to rise in the early 2010s, which meant patients were reaching care late, with nerve damage already done. This prompted door-to-door screening. The editorial welcomes the NSP’s focus on cutting transmission, in line with the WHO’s strategy, as the right correction.

3. Children are the measure. India’s children accounted for around 46 per cent of all child cases reported worldwide in 2025. Because child cases reveal recent transmission, the editorial says the child-focused and adult-focused efforts must move in tandem.

4. An uneven map. The decline has been highly uneven. Chhattisgarh, Jharkhand, Odisha and Maharashtra carry a disproportionate share of the national burden. Only 148 districts have achieved interruption of transmission, and that is pending field verification, against a projected 300.

5. The effort is real. The editorial records the scale of work in 2025-26:

The government has also put digital surveillance in place and is considering the MIP vaccine to speed up clearance of the pathogen in patients judged highly infectious.

6. The gap in care. Research shows that many patients already have nerve damage by the time they seek care, largely because of stigma. Many clinicians are unfamiliar with the disease and misdiagnose it as a skin condition. Both delay treatment, and every month of delay is a month of possible spread and of irreversible damage.

7. The prescription. The editorial makes three demands:

• Double down on interrupting transmission and treat prevalence as a secondary outcome.
• Resist the temptation to ease detection or revise targets. Incidence overshot projections by 41 per cent, child incidence by 91.6 per cent and the grade-2 disability rate by 34 per cent. The answer is to redouble investment to meet the existing 2026-27 projections, not to move the goalposts.
• Concentrate effort on the places and social settings where late diagnosis and transmission remain entrenched.

Data and Institutions Vault

Prelims-grade facts:

The 2025-26 picture (NLEP report, as reported by The Hindu):

• Districts with interruption of transmission: 148 (pending field verification), against 300 projected.
• Overshoot against projections: incidence 41%, child incidence 91.6%, grade-2 disability rate 34%.
• New cases 91,783; child cases 3,832 (target 2,000); G2D rate 1.34 per million population.
• India’s share of the world’s child cases in 2025: about 46%.
• High-burden States named: Chhattisgarh, Jharkhand, Odisha, Maharashtra.

Tools of the programme:

• Active case detection and door-to-door screening; ASHA-led referral.
• SDR-PEP: single-dose rifampicin post-exposure prophylaxis for contacts.
• Nikusth 2.0: web portal for case reporting.
• MIP (Mycobacterium indicus pranii): an India-developed immunomodulator, under consideration for highly infectious patients.
• Sparsh Leprosy Awareness Campaign and Anti-Leprosy Day on 30 January, Mahatma Gandhi’s death anniversary, a historic link to his care for leprosy patients.

Policy framework:

• NSP and Roadmap for Leprosy 2023-27: zero transmission at district level by 2027; zero disability among new child cases; zero stigma.
• WHO Global Leprosy Strategy 2021-2030, “Towards zero leprosy”.
• “Elimination as a public health problem”: prevalence below 1 per 10,000; India reached it in 2005.

⚠️ Watch the trap: Elimination is not eradication. India “eliminated leprosy as a public health problem” in 2005 by bringing prevalence below 1 per 10,000; the disease was never eradicated, and India still reports the most new cases in the world. Interruption of transmission is a third, higher bar: no new indigenous child cases for five consecutive years in a district.

The Debate

For the editorial’s view. The numbers are hard to argue with. When child incidence runs at almost double the projection and disability at diagnosis rises, transmission is continuing and diagnosis is late. Prevalence, which looks good, hides both. Easing detection to make the figures look better would repeat the mistake of 2005. Keeping the existing projections forces the system to find and treat the hidden cases.

The other side. Part of the overshoot is an artefact of better searching. When the programme screens 70 crore people and follows up 40 lakh suspected cases, it will find cases that would otherwise have gone unrecorded. Higher numbers in the short run are the expected result of active case-finding, and they may be a sign of success. There is also a risk the editorial does not discuss: targets set too tightly can encourage under-reporting at district level, the opposite of what the programme wants.

The balanced verdict. Both points can be true. Rising counts from intense screening are welcome, but child cases and G2D at diagnosis are not easily explained by better searching alone: they point to transmission and delay. The right response is to keep both the search intensity and the targets, while judging districts by the trend in child cases over several years rather than a single year’s count.

How to Think About This

Choose the indicator that matches the goal. Prevalence measures the burden on the health system; incidence measures whether the disease is spreading. A programme that wants to end a disease must track the second. Use this in any answer on disease control: India’s TB programme similarly moved from case notification to incidence estimates, and malaria elimination is judged by indigenous transmission.

Vertical versus horizontal programmes. Folding a disease-specific programme into general health services saves money and strengthens primary care, but can erode specialised skills when a disease becomes rare. The lesson is not to avoid integration, but to keep surveillance and expertise alive after a disease stops being visible.

Stigma is an epidemiological factor. Fear of social rejection makes patients hide symptoms, which delays treatment and extends the period in which they can infect others. Anti-stigma work is therefore not only a rights issue but a disease-control tool.

Diagram-in-Words

Takeaway Box

• Thesis: measure leprosy control by transmission, not prevalence, and do not move the targets.
• History: elimination as a public health problem in 2005; complacency and integration into general services followed; disability rose in the early 2010s.
• Status (2025-26): 148 districts with interrupted transmission against 300 projected; incidence 41%, child incidence 91.6% and G2D 34% above projections.
• Effort: over 70 crore screened; nearly 40 lakh suspected cases flagged by ASHAs; rifampicin PEP for 91.1% of 16.9 lakh contacts.
• Gaps: stigma, late care, misdiagnosis as a skin disease; burden concentrated in Chhattisgarh, Jharkhand, Odisha, Maharashtra.

Sources: The Hindu, editorial, 7 October 2026; background: The Hindu, 4 October 2026, DGHS, NLEP

Source: Break the Chain: Leprosy in India and the 2027 Goal — Ujiyari.com | Free UPSC & State PCS Editorial Analysis